Mary Caffrey
Mary Caffrey is the Executive Editor for The American Journal of Managed Care® (AJMC®). She joined AJMC® in 2013 and is the primary staff editor for Evidence-Based Oncology, the multistakeholder publication that reaches 22,000+ oncology providers, policy makers and formulary decision makers. She is also part of the team that oversees speaker recruitment and panel preparations for AJMC®'s premier annual oncology meeting, Patient-Centered Oncology Care®. For more than a decade, Mary has covered ASCO, ASH, ACC and other leading scientific meetings for AJMC readers.
Mary has a BA in communications and philosophy from Loyola University New Orleans. You can connect with Mary on LinkedIn.
Articles
City of Hope’s Dr Tycel Phillips Discusses Promise of Glofitamab in Heavily Pretreated MCL
Glofitamab is currently being investigated in a phase 1/2, multicenter, open-label, dose-escalation study as monotherapy and in combination with obinutuzumab, following 1-time fixed-dose pretreatment with obinutuzumab for B-cell non-Hodgkin lymphoma, of which mantle cell lymphoma (MCL) is a rare type.
“End-to-End” Strategies Achieve Better Enrollment, Diversity, and Data Collection in Clinical Trials
What Is a Health Plan’s Role in Preventing Homelessness Among Seniors?
The CEO of SCAN Health Plan discusses its first-ever Environmental, Social, and Governance Report.
Some experts believe offering a subcutaneous version of nivolumab could make PD-1 inhibitors available to new groups of patients who currently lack access, such as those in rural areas.
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Posters Detail Effects—and Uncertainty—of Drug Pricing Negotiations
Research into the Inflation Reduction Act evaluated payer concerns, patient and physician behavior, which patients will benefit from the first 10 drugs selected for price negotiation, and the ripple effect into Medicaid at the state level.
